1Plunker W, Liliemark JO, Adams TM. Saturation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-β-D-arabinofuranosylcytosine therapy. Cancer Res, 1987,47:3005.
2Kucera GL, Capizzi RL. 1-β-D-arabinofuranosylcytosine-diphosphate-choline is formed by the reversal of cholinephosphotransferase and not via cytidylytransferase.Cancer Res, 1992,52 : 3886.
3Kharbanda S,Emoto Y,Kisaki H. 1-β-D-arabinofuranosylcytosine activates serine/threonine protein kinases and c-jun gene expression in phorbol ester-resistant myeloid leukemia cells. Mol Pharmacol, 1994,46:67.
4Emoto Y, Kisaki H, Manome Y. Activation of protein kinase Cδ in human myeloid leukemia cells treated with 1-β-D-arabinofuranosylcytosine. Blood, 1996,87 : 1990.
5Gunji H,Kharbanda S,Kufe D. Induction of intemucleosomal DNA fragmentation in human myeloid leukemia cells by 1-β-D-arabinofuranosylcytosine. Cancer Res, 1991,51 :741.
6Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood, 1997,89 : 1845.
7Cassileth PA, Lynch E, Hines JD. Varying intensity of postremission therapy in acute myeloid leukemia. Blood, 1992,79 : 1924.
8Weick JK, Kopecky KJ, Appelbaum FR.Randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia:a southwest oncology group study. Blood,1996,88:2841.
9Karanes C, Kopecky K J, Head DR. A phase Ⅲ comparison of high-dose Ara-c versus HIDAC plus mitoxantrene in the treatment of first relapsed or refractory acute myeloid leukemia:a southwest oncology group study. Leukemia Res, 1999,23 :787.
10Bloomfield CD, Lawrence D, Byrd JC. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res,1998,58:4173.
